Their advancements in computational pathology will give pathologists improved precision and new insights.
PathAI is looking to transform pathology through its application of artificial intelligence to the industry with a focus on cancer diagnosis. Currently, pathologists are tasked with looking for cancerous cells in hundreds of specimens every day. Studies suggest that a diagnostic error occurs 10-15% of the time, which can have significant consequences for the patient.
PathAI wants to reduce the chance of human error and increase efficiency by developing technology that will improve both the speed of diagnosis and the accuracy.
Finding a few cancerous cells among thousands of healthy ones is a visual task that’s very well suited for AI. By applying deep learning, the technology can help predict how the disease will respond to different treatments.
PathAI has already proven successful in a recent trial when used to analyse non-alcoholic steatohepatitis (NASH) in liver biopsy samples. The innovative company has a strong team of over 60 doctors, pathologists and engineers. Their advancements in pathology will save lives by increasing early diagnosis, reducing human error, and accurately matching the right treatments for the disease.